FORDYCE MARSHALL (President and CEO) sold 8.8% of their position (19.69K shares) of VERA THERAPEUTICS, INC. on the open market
Open‑market sale worth $546.9K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 2/27/2025ACC: 0001415889-25-005841
DirectorOfficer· President and CEO
Since May 2021
-19.69K
Net shares
Net seller
$546.9K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
19.69K disposed
Non-Derivative Transactions3
Class A Common Stock
Direct
Shares
−10.61K
Price / share
$27.89
Trade value
$296.03K
% of position
4.7%
2/21/2025
224.35K→213.74K
Class A Common Stock
Direct
Shares
−7.97K
Price / share
$27.55
Trade value
$219.73K
% of position
3.7%
2/26/2025
213.74K→205.76K
Class A Common Stock
Direct
Shares
−1.10K
Price / share
$28.32
Trade value
$31.15K
% of position
0.5%
2/26/2025
205.76K→204.66K
Total
Net shares
−19.69K
Net value
-$546.91K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock Direct | 2/21/2025 | S · Sale | −10.61K | $27.89 | $296.03K | 4.7% | 224.35K | 213.74K |
| Class A Common Stock Direct | 2/26/2025 | S · Sale | −7.97K | $27.55 | $219.73K | 3.7% | 213.74K | 205.76K |
| Class A Common Stock Direct | 2/26/2025 | S · Sale | −1.10K | $28.32 | $31.15K | 0.5% | 205.76K | 204.66K |
| Total | −19.69K | -$546.91K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Class A Common Stock
IndirectShares owned222.03K
Total
222.03K indirect222.03K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Class A Common Stock | 222.03K | Indirect |
| Total | 222.03K | 222.03K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported